drugset
drugset / Trial / NCT01874665

A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor

NCT01874665 ↗

Phase 2 Completed 45 enrolled Ariad Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of ponatinib in participants with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) following failure of prior tyrosine kinase inhibitor (TKI) therapy.

Timeline

Start
2013-06-05
Primary completion
2015-02-28
Completion
2016-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ponatinib Small molecule 45 mg Oral

Indications

gastrointestinal stromal tumor